RxDoctor Payments Data

Vanessa Mischler, NP

Nurse Practitioner · Evansville, INNPI 1104508993

Payments from drug & device makers

$6,788in general payments, 2019–2025

Across 390 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$866
  • UCB, Inc.$844
  • AbbVie$766
  • Dermavant Sciences, Inc.$564
  • Regeneron Healthcare Solutions, Inc.$521
  • E.r. Squibb & Sons, L.L.C.$505
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$6,55997%
  • Education$2293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,788 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$40,734
Medicare patients
245
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab43$361,864
RinvoqUpadacitinib51$351,603
TremfyaGuselkumab11$143,299
Dupixent PenDupilumab37$138,767
OtezlaApremilast14$65,596
JubliaEfinaconazole11$8,363
Clobetasol Propionate108$5,185
Betamethasone Valerate110$2,993
Tretinoin15$1,071
Minoxidil60$913
Ketoconazole71$846
Minocycline Hcl27$752
Clindamycin Phos-Benzoyl PeroxClindamycin Phos/Benzoyl Perox13$617
Cephalexin43$612
Hydroxyzine Hcl54$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$766$351,60351 claims
Johnson & JohnsonTremfya$866$143,29911 claims
AmgenOtezla$34$65,59614 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$269$8,36311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →